Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and Refractory CD5 Hematological Tumors”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Not applicableLooking for participantsNCT07234110
What this trial is testing

CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

Who this might be right for
Relapsed and Refractory CD5 Hematological Tumors
Institute of Hematology & Blood Diseases Hospital, China 18
Testing effectiveness (Phase 2)Looking for participantsNCT05110742
What this trial is testing

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Who this might be right for
Hematological Malignancy
M.D. Anderson Cancer Center 64
Very early researchUnknownNCT04767308
What this trial is testing

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Who this might be right for
CD5+ Relapsed/Refractory Hematopoietic MalignanciesChronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)+3 more
Huazhong University of Science and Technology 18
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Early research (Phase 1)Looking for participantsNCT06909474
What this trial is testing

Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies

Who this might be right for
T-ALL/Lymphoma
Chongqing Precision Biotech Co., Ltd 15